Eli Lilly Shares Surge on 57 Billion Dollar Trading Day as UK Drug Price Hike Sparks Global Pricing Debate

Eli Lilly (LLY) surged 2.45% on August 15, 2025, with a trading volume of $5.73 billion, ranking 13th in market activity. The move followed the company’s announcement to increase the UK list price of its diabetes and weight-loss drug Mounjaro (tirzepatide) by up to 170%, effective September 1. The price hike, ranging from £133 to £330 per month depending on dosage, aligns with global pricing strategies amid pressure from U.S. President Donald Trump to reduce domestic drug costs through international price comparisons. Eli Lilly emphasized that NHS access remains unchanged, but private healthcare providers may face higher costs. The drug, which generated $5.2 billion in Q2 2025 sales, has been a key growth driver as demand for weight-loss treatments intensifies globally.

The decision to raise prices in the UK follows a discounted launch in early 2024 to expedite NHS access. Analysts note the move reflects broader industry efforts to harmonize pricing across developed markets, though patient affordability concerns persist. Independent Pharmacies Association CEO Dr. Leyla Hannbeck criticized the increase, warning it could deter average patients from accessing treatments. Eli Lilly defended the adjustment as necessary to address pricing inconsistencies but rejected Trump’s Most Favoured Nation policy, arguing it undermines innovation funding. The company’s strategic focus on expanding global access while balancing revenue remains central to its market positioning.

The strategy of buying the top 500 stocks by daily trading volume and holding them for 1 day from 2022 to now delivered moderate returns. The 1-day return was 0.98% and the total return was 37.61%. While the strategy showed stability, the returns were relatively modest, indicating a conservative performance compared to potential high-risk, high-reward strategies.